Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.
Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.
It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.84 Decreased by -37.70% | -0.64 Decreased by -31.25% |
| Mar 7, 24 | -0.75 Decreased by -457.14% | -0.15 Decreased by -400.00% |
| Nov 6, 23 | 0.28 Increased by +170.00% | -0.10 Increased by +380.00% |
| Aug 9, 23 | -0.69 Decreased by -2.99% | -0.52 Decreased by -32.69% |
| May 9, 23 | -0.61 Increased by +43.52% | 0.45 Decreased by -235.56% |
| Mar 15, 23 | 0.21 Increased by +122.11% | 0.10 Increased by +110.00% |
| Nov 3, 22 | -0.40 Increased by +53.49% | -0.38 Decreased by -5.26% |
| Aug 8, 22 | -0.67 Decreased by -1.52% | -0.97 Increased by +30.93% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 10.40 M Decreased by -75.09% | 17.55 M Increased by +171.15% | Increased by +168.84% Increased by +385.61% |
| Jun 30, 23 | 13.14 M Decreased by -49.49% | 57.47 M Increased by +240.86% | Increased by +437.49% Increased by +378.87% |
| Mar 31, 23 | 24.21 M Increased by +126.86% | -38.25 M Increased by +42.27% | Decreased by -157.96% Increased by +74.55% |
| Dec 31, 22 | 71.18 M Increased by +422.43% | 12.80 M Increased by +122.06% | Increased by +17.99% Increased by +104.22% |
| Sep 30, 22 | 41.73 M Increased by +167.92% | -24.67 M Increased by +53.35% | Decreased by -59.11% Increased by +82.59% |
| Jun 30, 22 | 26.01 M Decreased by -14.37% | -40.80 M Decreased by -2.17% | Decreased by -156.88% Decreased by -19.31% |
| Mar 31, 22 | 10.67 M Decreased by -33.59% | -66.25 M Decreased by -29.21% | Decreased by -620.71% Decreased by -94.56% |
| Dec 31, 21 | 13.62 M Decreased by -73.67% | -58.02 M Decreased by -2.68 K% | Decreased by -425.88% Decreased by -10.46 K% |